Max SoegaardDirector, Process Development at ExpreS2ion Biotechnologies
Max Søgaard joined Expres2ion Biotechnologies in 2013 to set up a protein purification and characterisation department. Working closely with clients he has since helped to convert non-cGMP, lab-scale protocols into fully scalable, reproducible, cGMP compliant processes in a number of projects currently in clinical phase I/II trials. Max and a small team of scientists and technicians are working to expand the up- and downstream and analytical capabilities within Expres2ion Biotechnologies to meet the individual and diverse challenges of proteins for vaccine-antigens, diagnostics and therapeutics. Max has a background in the field of structural protein biochemistry at University of Oxford as well as mechanisms of basal transcription (Ph.D., Clare Hall, Cancer Research UK) and translation termination (Cand.Scient, University of Aarhus, Denmark).